Safe Medication Use
ID: FDA-RFI-126495Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFFOOD AND DRUG ADMINISTRATIONFDA CENTER FOR DRUG EVALUATION AND RESEARCHSilver Spring, MD, 20993, USA

NAICS

All Other Professional, Scientific, and Technical Services (541990)

Original Source

https://sam.gov/opp/9ae04c73a15f484e85d7546a1edef206/view
Timeline
    Description

    The U.S. Food and Drug Administration (FDA) is conducting a Request for Information (RFI) to identify potential sources capable of providing medication error reports, an analytics platform, and related services aimed at preventing and analyzing medication errors. This initiative, led by the FDA's Center for Drug Evaluation and Research, seeks organizations that can supply nationwide data from healthcare providers, consumers, and patient safety organizations, emphasizing the importance of robust reporting, data analysis, and training in enhancing medication safety protocols. Interested parties, particularly small businesses, are encouraged to submit their capability statements by January 6th, 2025, and should note that responses are voluntary and do not imply a commitment for a contract. For further inquiries, contact Brian Wodzisz at Brian.Wodzisz@fda.hhs.gov or call 301-796-7376.

    Point(s) of Contact
    Brian Wodzisz
    (301) 796-7376
    Brian.Wodzisz@fda.hhs.gov
    Files
    Title
    Posted
    RFI_SafeMedUse.pdf
    The FDA's Center for Drug Evaluation and Research (CDER) is seeking information through a Request for Information (RFI) to explore potential sources for medication error reports, an analytics platform, and related services aimed at preventing and analyzing medication errors. This initiative, driven by the Office of Surveillance and Epidemiology, targets organizations capable of providing nationwide data collected from healthcare providers, consumers, and patient safety organizations. The RFI emphasizes that responses are voluntary and do not imply a commitment for a contract. Vendors must demonstrate specific capabilities and provide detailed capability statements, showcasing their experience and insights on cost-effective solutions, risk mitigation, and resource requirements. The project's objectives include robust reporting, data analysis, and training, underpinned by the necessity for rigorous data management and responsiveness to public health concerns. The FDA encourages small businesses to participate and highlights its rights to utilize submitted non-proprietary data in future solicitations. Responses are due by January 6th, 2025, emphasizing the FDA's commitment to enhancing medication safety protocols through informed partnerships.
    Lifecycle
    Title
    Type
    Safe Medication Use
    Currently viewing
    Sources Sought
    Similar Opportunities
    FDA Regulated Products Sampling Services
    Active
    Health And Human Services, Department Of
    The U.S. Food and Drug Administration (FDA) is seeking qualified vendors to provide Sampling Services for FDA-regulated products through a Sources Sought Notice (Ref No. 75F40125R00032). The primary objective of this procurement is to identify capable businesses that can collect physical samples of food, drugs, medical devices, and other products for laboratory analysis, ensuring safety and verifying labeling accuracy. This initiative is crucial for the FDA's regulatory oversight, as it supports the monitoring of product safety and quality, which may include both domestic and imported goods. Interested parties must submit their responses by January 9, 2025, and can contact Amanda Lusk at Amanda.Lusk@fda.hhs.gov or Nicholas Bisher at Nicholas.Bisher@fda.hhs.gov for further information.
    PRIMO Software Licensing
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide PRIMO Software Licensing and Maintenance Support Services. The procurement involves supplying 21 PRIMO software licenses for a base year, with two additional option years, to ensure the continuous operation of the FDA's CFSAN CAEMS system. This software is crucial for pharmacovigilance and regulatory compliance, enhancing the FDA's capabilities in monitoring food safety. Interested parties must submit their quotes by August 26, 2024, and are encouraged to contact Roosevelt Walker at roosevelt.walker@fda.hhs.gov for further details. The contract will be awarded as a firm-fixed-price purchase order, emphasizing compliance with federal acquisition regulations and accessibility standards.
    FY25 Docker Enterprise Edition Licenses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking proposals for the procurement of Docker Enterprise Edition licenses to support the development of its Containers as a Service (CaaS) platform. The objective of this contract is to enhance the FDA's IT infrastructure by utilizing Docker EE’s container technology, which is essential for improving operational efficiency and reducing costs compared to traditional virtual machines. This procurement is significant as it enables the FDA to deploy applications in various environments while ensuring compliance with federal security mandates. Interested small businesses must submit their quotes by January 2, 2025, and can direct inquiries to Terina Hicks at terina.hicks@fda.hhs.gov or Roosevelt Walker at roosevelt.walker@fda.hhs.gov.
    Request for Information - Enhancing Pharmacy Countermeasures in Independent Pharmacies
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking insights through a Request for Information (RFI) aimed at enhancing pharmacy countermeasures in independent pharmacies. The objective is to gather information from pharmacy partners, vendors, and associations regarding the necessary capabilities and infrastructure for independent pharmacies to effectively deliver health services, including testing, vaccines, and therapeutics, particularly to under-resourced populations. This initiative is crucial as independent pharmacies play a vital role in public health, especially in rural areas, and the information collected will inform strategies to improve service delivery and public health response capacity. Interested parties can contact Dawn Redman at dredman@cdc.gov or call 404-498-3069 for further details.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Access to the Florence electronic Trial Master File (eTMF) Platform- 12 Months Annual Subscription
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure a 12-month annual subscription to the Florence electronic Trial Master File (eTMF) platform. This non-competitive solicitation aims to secure a commercial item necessary for secure data storage and management for the Rare Disease Clinical Research Network (RDCRN) program, ensuring continuity and compliance with existing systems currently in use. Interested vendors must submit their quotations by 1:00 p.m. Eastern Time on December 24, 2024, referencing Solicitation Number 75N95025Q00050, and can direct inquiries to Samson Shifaraw at samson.shifaraw@nih.gov or by phone at 301-480-7153.
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The primary objective is to identify suppliers capable of providing FDA-approved medications, including Amoxicillin, Ciprofloxacin, and Clindamycin, in specified formulations and quantities, as detailed in the associated RFI documents. This procurement is crucial for ensuring rapid access to essential medical supplies during public health emergencies, such as biological or chemical threats and natural disasters. Interested vendors must submit their capabilities and relevant information electronically by January 9, 2025, to Terri Reed at terri.reed@hhs.gov, with the understanding that responses will not be returned and will be treated as public knowledge.
    FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), has announced the FY24 Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science. This opportunity aims to support innovative research projects that enhance regulatory science, with a focus on health, medical, and biotechnology advancements. The awarded contracts, totaling over $24 million, cover a range of critical topics including drug safety, gene therapy, and methodologies for assessing pediatric opioid exposure, reflecting the federal government's commitment to fostering research initiatives that improve healthcare delivery and regulatory processes. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    DA10--Patient Safety Technology
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to issue a Firm-Fixed Price contract to Invisalert Solutions for the ObservSMART system, which employs proprietary software and advanced wristband technology to enhance patient safety and compliance in healthcare settings. This innovative system utilizes a highly tamper-resistant wristband equipped with a Bluetooth beacon and a tablet to facilitate real-time patient observations, ensuring that checks can only occur when staff are in close proximity to patients, thereby reducing the risks of missed or falsified observations. Interested parties are invited to submit capability statements to the designated contact, Becky De Los Santos, by 10:00 PM CST on December 27, 2024, to potentially influence the decision on whether the contract will be competitively bid. Responses should include specific organizational information and business status classifications, as outlined in the notice.
    Bruker Maldi TOF Maintenance
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking proposals for a full-service maintenance agreement for its Bruker MALDI TOF system, with a contract start date of January 16, 2025, and four optional one-year extensions. The contractor will be responsible for comprehensive maintenance services, including all repairs, annual preventative maintenance, and ensuring compliance with regulatory standards, with a focus on supporting the FDA's mission to monitor antimicrobial resistance in foodborne and zoonotic pathogens. Interested small businesses must submit their quotes by 11:59 PM EST on January 3, 2025, and can direct inquiries to James O’Keefe at 301-796-7371 or via email at James.OKeefeIII@fda.hhs.gov.